ELIZABETH FERNANDES, M.D.; F. MICHAEL MELEWICZ, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: The newly available histamine (H2) receptor antagonist, ranitidine hydrochloride (Zantac; Glaxo Inc. , Fort Lauderdale, Florida) has been approved for short-term treatment of duodenal ulcer. Ranitidine is four to eight times more potent than Cimetidine for inhibiting gastric acid secretions (1). As the use of ranitidine increases, reports of its interaction with other drugs such as warfarin and metoprolol are appearing (2). We report a case of theophylline toxicity induced by toxic elevation of serum theophylline levels after initiation of ranitidine therapy.
A 75-year-old man with a history of chronic obstructive pulmonary disease with bronchospasm, peptic ulcer
FERNANDES E, MELEWICZ FM. Ranitidine and Theophylline. Ann Intern Med. ;100:459. doi: 10.7326/0003-4819-100-3-459_1
Download citation file:
Published: Ann Intern Med. 1984;100(3):459.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use